Ever op­ti­mistic de­spite con­cerns, Brain­Storm teams with Catal­ent to prep for pos­si­ble ap­proval for ALS drug

Catal­ent has en­tered a part­ner­ship with a cell ther­a­py com­pa­ny that fo­cus­es on neu­rode­gen­er­a­tive dis­eases, tak­ing on a tech trans­fer to man­u­fac­ture treat­ments for ALS and PMS.

Brain­Storm Cell Ther­a­peu­tics and Catal­ent have been part­ners since 2020, when Catal­ent start­ed man­u­fac­tur­ing NurOwn, the amy­otroph­ic lat­er­al scle­ro­sis plat­form com­prised of mes­enchy­mal stem cells (MSCs) and neu­rotroph­ic fac­tors, in an­tic­i­pa­tion of a pos­si­ble reg­u­la­to­ry ap­proval. Catal­ent will use its 32,000-square-foot fa­cil­i­ty in Hous­ton, TX to man­u­fac­ture the cell ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER